Skip to main content
Erschienen in: Breast Cancer Research 6/2002

01.12.2002 | Review

Progesterone receptors - animal models and cell signaling in breast cancer Diverse activation pathways for the progesterone receptor - possible implications for breast biology and cancer

verfasst von: Claudia Lanari, Alfredo A Molinolo

Erschienen in: Breast Cancer Research | Ausgabe 6/2002

Einloggen, um Zugang zu erhalten

Abstract

Progesterone and estradiol, and their nuclear receptors, play essential roles in the physiology of the reproductive tract, the mammary gland and the nervous system. Estrogens have traditionally been considered associated with an increased risk of breast cancer. There is, however, compelling evidence that progesterone plays an important role in breast cell proliferation and cancer. Herein, we review the possible role of progestins and the progesterone receptor-associated signaling pathways in the development of breast cancer, as well as the therapeutic possibilities arising from our growing knowledge of the activation of the progesterone receptor by other proliferative mechanisms.
Literatur
1.
Zurück zum Zitat Goepfert TM, McCarthy M, Kittrell FS, Stephens C, Ullrich RL, Brinkley BR, Medina D: Progesterone facilitates chromosome instability (aneuploidy) in p53 null normal mammary epithelial cells. FASEB J. 2000, 14: 2221-2229. 10.1096/fj.00-0165com.CrossRefPubMed Goepfert TM, McCarthy M, Kittrell FS, Stephens C, Ullrich RL, Brinkley BR, Medina D: Progesterone facilitates chromosome instability (aneuploidy) in p53 null normal mammary epithelial cells. FASEB J. 2000, 14: 2221-2229. 10.1096/fj.00-0165com.CrossRefPubMed
2.
Zurück zum Zitat Women's Health Initiative: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002, 288: 321-333.CrossRef Women's Health Initiative: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002, 288: 321-333.CrossRef
3.
Zurück zum Zitat Ross RK, Paganini-Hill A, Wan PC, Pike MC: Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst. 2000, 92: 328-332. 10.1093/jnci/92.4.328.CrossRefPubMed Ross RK, Paganini-Hill A, Wan PC, Pike MC: Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst. 2000, 92: 328-332. 10.1093/jnci/92.4.328.CrossRefPubMed
4.
Zurück zum Zitat Klijn JG, Setyono-Han B, Foekens JA: Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids. 2000, 65: 825-830. 10.1016/S0039-128X(00)00195-1.CrossRefPubMed Klijn JG, Setyono-Han B, Foekens JA: Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids. 2000, 65: 825-830. 10.1016/S0039-128X(00)00195-1.CrossRefPubMed
5.
Zurück zum Zitat Lanari C, Molinolo AA, Pasqualini CD: Inhibitory effect of medroxyprogesterone acetate on foreign body tumorigenesis in mice. J Natl Cancer Inst. 1986, 77: 157-164.PubMed Lanari C, Molinolo AA, Pasqualini CD: Inhibitory effect of medroxyprogesterone acetate on foreign body tumorigenesis in mice. J Natl Cancer Inst. 1986, 77: 157-164.PubMed
6.
Zurück zum Zitat Molinolo AA, Lanari C, Charreau EH, Sanjuan N, Pasqualini CD: Mouse mammary tumors induced by medroxyprogesterone acetate: immunohistochemistry and hormonal receptors. J Natl Cancer Inst. 1987, 79: 1341-1350.PubMed Molinolo AA, Lanari C, Charreau EH, Sanjuan N, Pasqualini CD: Mouse mammary tumors induced by medroxyprogesterone acetate: immunohistochemistry and hormonal receptors. J Natl Cancer Inst. 1987, 79: 1341-1350.PubMed
7.
Zurück zum Zitat Lanari C, Kordon E, Molinolo A, Pasqualini CD, Charreau EH: Mammary adenocarcinomas induced by medroxyprogesterone acetate: hormone dependence and EGF receptors of BALB/c in vivo sublines. Int J Cancer. 1989, 43: 845-850.CrossRefPubMed Lanari C, Kordon E, Molinolo A, Pasqualini CD, Charreau EH: Mammary adenocarcinomas induced by medroxyprogesterone acetate: hormone dependence and EGF receptors of BALB/c in vivo sublines. Int J Cancer. 1989, 43: 845-850.CrossRefPubMed
8.
Zurück zum Zitat Nagasawa H, Aoki M, Sakagami N, Ishida M: Medroxyprogesterone acetate enhances spontaneous mammary tumorigenesis and uterine adenomyosis in mice. Breast Cancer Res Treat. 1988, 12: 59-66.CrossRefPubMed Nagasawa H, Aoki M, Sakagami N, Ishida M: Medroxyprogesterone acetate enhances spontaneous mammary tumorigenesis and uterine adenomyosis in mice. Breast Cancer Res Treat. 1988, 12: 59-66.CrossRefPubMed
9.
Zurück zum Zitat Kordon EC, Molinolo AA, Pasqualini CD, Charreau EH, Pazos P, Dran G, Lanari C: Progesterone induction of mammary carcinomas in BALB/c female mice. Correlation between progestin dependence and morphology. Breast Cancer Res Treat. 1993, 28: 29-39.CrossRefPubMed Kordon EC, Molinolo AA, Pasqualini CD, Charreau EH, Pazos P, Dran G, Lanari C: Progesterone induction of mammary carcinomas in BALB/c female mice. Correlation between progestin dependence and morphology. Breast Cancer Res Treat. 1993, 28: 29-39.CrossRefPubMed
10.
Zurück zum Zitat Pazos P, Lanari C, Meiss R, Charreau EH, Pasqualini CD: Mammary carcinogenesis induced by I-methyl-I-nitrosourea (MNU) and medroxyprogesterone acetate (MPA) in BALB/c mice. Breast Cancer Res Treat. 1992, 20: 133-138.CrossRefPubMed Pazos P, Lanari C, Meiss R, Charreau EH, Pasqualini CD: Mammary carcinogenesis induced by I-methyl-I-nitrosourea (MNU) and medroxyprogesterone acetate (MPA) in BALB/c mice. Breast Cancer Res Treat. 1992, 20: 133-138.CrossRefPubMed
11.
Zurück zum Zitat Aldaz CM, Liao QY, Paladugu A, Rehm S, Wang H: Allelotypic and cytogenetic characterization of chemically induced mouse mammary tumors: high frequency of chromosome 4 loss of heterozygosity at advanced stages of progression. Mol Carcinog. 1996, 17: 126-133. 10.1002/(SICI)1098-2744(199611)17:3<126::AID-MC4>3.0.CO;2-D.CrossRefPubMed Aldaz CM, Liao QY, Paladugu A, Rehm S, Wang H: Allelotypic and cytogenetic characterization of chemically induced mouse mammary tumors: high frequency of chromosome 4 loss of heterozygosity at advanced stages of progression. Mol Carcinog. 1996, 17: 126-133. 10.1002/(SICI)1098-2744(199611)17:3<126::AID-MC4>3.0.CO;2-D.CrossRefPubMed
12.
Zurück zum Zitat Lydon JP, Ge G, Kittrell FS, Medina D, O'Malley BW: Murine mammary gland carcinogenesis is critically dependent on progesterone receptor function. Cancer Res. 1999, 59: 4276-4284.PubMed Lydon JP, Ge G, Kittrell FS, Medina D, O'Malley BW: Murine mammary gland carcinogenesis is critically dependent on progesterone receptor function. Cancer Res. 1999, 59: 4276-4284.PubMed
13.
14.
Zurück zum Zitat Lange CA, Richer JK, Horwitz KB: Hypothesis: progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol Endocrinol. 1999, 13: 829-836. 10.1210/me.13.6.829.CrossRefPubMed Lange CA, Richer JK, Horwitz KB: Hypothesis: progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol Endocrinol. 1999, 13: 829-836. 10.1210/me.13.6.829.CrossRefPubMed
15.
Zurück zum Zitat Lamb C, Simian M, Molinolo A, Pazos P, Lanari C: Regulation of cell growth of a progestin-dependent murine mammary carcinoma in vitro: progesterone receptor involvement in serum or growth factor-induced cell proliferation. J Steroid Biochem Mol Biol. 1999, 70: 133-142. 10.1016/S0960-0760(99)00108-9.CrossRefPubMed Lamb C, Simian M, Molinolo A, Pazos P, Lanari C: Regulation of cell growth of a progestin-dependent murine mammary carcinoma in vitro: progesterone receptor involvement in serum or growth factor-induced cell proliferation. J Steroid Biochem Mol Biol. 1999, 70: 133-142. 10.1016/S0960-0760(99)00108-9.CrossRefPubMed
16.
Zurück zum Zitat Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB: Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem. 2002, 277: 5209-5218. 10.1074/jbc.M110090200.CrossRefPubMed Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB: Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem. 2002, 277: 5209-5218. 10.1074/jbc.M110090200.CrossRefPubMed
17.
Zurück zum Zitat Shyamala G, Yang X, Cardiff RD, Dale E: Impact of progesterone receptor on cell-fate decisions during mammary gland development. Proc Natl Acad Sci USA. 2000, 97: 3044-3049. 10.1073/pnas.97.7.3044.CrossRefPubMedPubMedCentral Shyamala G, Yang X, Cardiff RD, Dale E: Impact of progesterone receptor on cell-fate decisions during mammary gland development. Proc Natl Acad Sci USA. 2000, 97: 3044-3049. 10.1073/pnas.97.7.3044.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat McKenna NJ, Lanz RB, O'Malley BW: Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev. 1999, 20: 321-344. 10.1210/er.20.3.321.PubMed McKenna NJ, Lanz RB, O'Malley BW: Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev. 1999, 20: 321-344. 10.1210/er.20.3.321.PubMed
19.
Zurück zum Zitat Giangrande PH, McDonnell DP: The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene. Recent Prog Horm Res. 1999, 54: 291-313.PubMed Giangrande PH, McDonnell DP: The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene. Recent Prog Horm Res. 1999, 54: 291-313.PubMed
20.
Zurück zum Zitat Clemm DL, Sherman L, Boonyaratanakornkit V, Schrader WT, Weigel NL, Edwards DP: Differential hormone-dependent phosphorylation of progesterone receptor A and B forms revealed by a phosphoserine site-specific monoclonal antibody. Mol Endocrinol. 2000, 14: 52-65. 10.1210/me.14.1.52.CrossRefPubMed Clemm DL, Sherman L, Boonyaratanakornkit V, Schrader WT, Weigel NL, Edwards DP: Differential hormone-dependent phosphorylation of progesterone receptor A and B forms revealed by a phosphoserine site-specific monoclonal antibody. Mol Endocrinol. 2000, 14: 52-65. 10.1210/me.14.1.52.CrossRefPubMed
21.
Zurück zum Zitat Edwards DP, Weigel NL, Nordeen SK, Beck CA: Modulators of cellular protein phosphorylation alter the trans-activation function of human progesterone receptor and the biological activity of progesterone antagonists. Breast Cancer Res Treat. 1993, 27: 41-56.CrossRefPubMed Edwards DP, Weigel NL, Nordeen SK, Beck CA: Modulators of cellular protein phosphorylation alter the trans-activation function of human progesterone receptor and the biological activity of progesterone antagonists. Breast Cancer Res Treat. 1993, 27: 41-56.CrossRefPubMed
22.
Zurück zum Zitat Jacobsen BM, Richer JK, Schittone SA, Horwitz KB: New human breast cancer cells to study progesterone receptor (PR) isoform ratio effects and ligand-independent gene regulation. J Biol Chem. 2002, 277: 27793-27800. 10.1074/jbc.M202584200.CrossRefPubMed Jacobsen BM, Richer JK, Schittone SA, Horwitz KB: New human breast cancer cells to study progesterone receptor (PR) isoform ratio effects and ligand-independent gene regulation. J Biol Chem. 2002, 277: 27793-27800. 10.1074/jbc.M202584200.CrossRefPubMed
23.
Zurück zum Zitat Elizalde P, Labriola L, Salatino M, Movsichoff F, Proietti C, Pecci A, Coso O, Kornblihtt A, Charreau E: Heregulin regulates the progesterone receptor (Pr) transcriptional activity by a mechanism that requires a functional erbB-2 and mitogen-activated protein kinases (MAPK) activation. In Proceedings of the AACR, New Orleans. Buenos Aires: Instituto de Biología y Medicina Experimental, and Facultad de Ciencias Exactas y Naturales, UBA; March. 2001, 24-28. Elizalde P, Labriola L, Salatino M, Movsichoff F, Proietti C, Pecci A, Coso O, Kornblihtt A, Charreau E: Heregulin regulates the progesterone receptor (Pr) transcriptional activity by a mechanism that requires a functional erbB-2 and mitogen-activated protein kinases (MAPK) activation. In Proceedings of the AACR, New Orleans. Buenos Aires: Instituto de Biología y Medicina Experimental, and Facultad de Ciencias Exactas y Naturales, UBA; March. 2001, 24-28.
24.
Zurück zum Zitat Migliaccio A, Piccolo D, Castoria G, Di Domenico M, Bilancio A, Lombardi M, Gong W, Beato M, Auricchio F: Activation of the Src/p21ras/Erk pathway by progesterone receptor via crosstalk with estrogen receptor. EMBO J. 1998, 17: 2008-2018. 10.1093/emboj/17.7.2008.CrossRefPubMedPubMedCentral Migliaccio A, Piccolo D, Castoria G, Di Domenico M, Bilancio A, Lombardi M, Gong W, Beato M, Auricchio F: Activation of the Src/p21ras/Erk pathway by progesterone receptor via crosstalk with estrogen receptor. EMBO J. 1998, 17: 2008-2018. 10.1093/emboj/17.7.2008.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Bardon S, Vignon F, Montcourrier P, Rochefort H: Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells. Cancer Research. 1987, 47: 1441-1448.PubMed Bardon S, Vignon F, Montcourrier P, Rochefort H: Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells. Cancer Research. 1987, 47: 1441-1448.PubMed
27.
Zurück zum Zitat Vanzulli S, Efeyan A, Benavides F, Helguero L, Peters G, Shen J, Conti CJ, Lanari C, Molinolo A: p21, p27 and p53 in estrogen and antiprogestin-induced tumor regression of experimental mouse mammary ductal carcinomas. Carcinogenesis. 2002, 23: 749-757. 10.1093/carcin/23.5.749.CrossRefPubMed Vanzulli S, Efeyan A, Benavides F, Helguero L, Peters G, Shen J, Conti CJ, Lanari C, Molinolo A: p21, p27 and p53 in estrogen and antiprogestin-induced tumor regression of experimental mouse mammary ductal carcinomas. Carcinogenesis. 2002, 23: 749-757. 10.1093/carcin/23.5.749.CrossRefPubMed
28.
Zurück zum Zitat Nishino Y, Schneider MR, Michna H: Enhancement of the anti-tumor efficacy of the antiprogestin, onapristone, by combination with the antiestrogen, ICI 164384. J Cancer Res Clin Oncol. 1994, 120: 298-302.CrossRefPubMed Nishino Y, Schneider MR, Michna H: Enhancement of the anti-tumor efficacy of the antiprogestin, onapristone, by combination with the antiestrogen, ICI 164384. J Cancer Res Clin Oncol. 1994, 120: 298-302.CrossRefPubMed
Metadaten
Titel
Progesterone receptors - animal models and cell signaling in breast cancer Diverse activation pathways for the progesterone receptor - possible implications for breast biology and cancer
verfasst von
Claudia Lanari
Alfredo A Molinolo
Publikationsdatum
01.12.2002
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 6/2002
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr539

Weitere Artikel der Ausgabe 6/2002

Breast Cancer Research 6/2002 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.